Did you mean?
Search Results - Showing 108 - 120 Of 132
_update-on-the-latest-in-parp-inhibitors-for-prostate-cancer.webp "Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) and Prof Bertrand Tombal (Université Catholique de Louvain, Brussels, Belgium) discuss the latest in PARP inhibitors for prostate cancer. Initially, Prof Tombal comments on the phase III PROpel trial which investigated the tolerability of abiraterone combined with olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). Prof Merseburger and Prof Tombal also discuss the health-related quali")
_anzgog-illumina-satellite-symposium.webp "Enabling Next Level Comprehensive Genomic Profiling with Gold-Standard Homologous Recombination Deficiency (HRD) Insights.")
_genome-engineering-and-the-future-of-medicine-inaugural-wyss-visionary-solutions-summit.webp "SpeakernnKeynote Speaker: George Church, Ph.D.nFounding Core Faculty & Lead, Synthetic BiologynWyss Institute at Harvard UniversitynnSpeaker BionnGeorge Church, Ph.D. is a Founding Core Faculty member of the Wyss Institute andna Professor at HMS, Harvard, and MIT. He is widely recognized for his innovativencontributions to genomic science, chemistry, and biomedicine. In 1984, hendeveloped the first direct genomic sequencing method, and helped initiate thenHuman Genome Project. He has also in")
⏲ 13 min 6 sec ✓ 03-Jun-2022
_esmo-2017-prostate-cancer-highlights.webp "Our panel of experts share their ESMO 2017 highlights and offer their opinion on current, and future standard-of-care within prostate cancer treatment. Some of the panels key highlights include additional STAMPEDE data which share further efficacy results; this time assessing the addition of abiraterone acetate plus prednisolone vs. docetaxel for patients with high risk prostate cancer starting long-term androgen deprivation therapy; and additional data from STAMPEDE looking at the outcomes in n")
_talazoparib-plus-enzalutamide-shows-improvement-in-pfs-over-standard-of-care-in-first-line-hrr-mcrpc.webp "Prof Karim Fizazi speaks to ecancer about the TALAPRO-2 phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring homologous recombination repair (HRR) gene alterations.nnThis study reports the results of the prespecified, independently powered analysis of patients with mCRPC with HRR gene alterations from Cohorts 1 and 2 of the TALAPRO-2 trial.nnThe results of this")
Talazoparib plus enzalutamide shows improvement in PFS over standard of care in first-line HRR mCRPC
⏲ 3 min 0 sec ✓ 06-Jun-2023
_evolution-organic-evolution-homologous-and-analogous-organs.webp "Evolution - Organic Evolution, Homologous And Analogous Organs from homologous")
_vis16-preview-synteny-explorer-an-interactive-visualization-application-for-teaching-genome-evolution.webp "SciVis Paper nnOrganizers / Panelists: Chris Bryan, Gregory Guterman, Kwan-Liu Ma, Harris Lewin, Denis Larkin, Jaebum Kim, Jian Ma, Marta FarrénnAbstract: Rapid advances in biology demand new tools for more active research dissemination and engaged teaching. This paper presents Synteny Explorer, an interactive visualization application designed to let college students explore genome evolution of mammalian species. The tool visualizes synteny blocks: segments of homologous DNA shared between var")
⏲ 30 sec ✓ 16-Sep-2016
_book-of-odes.webp "I found the respect for tradition of Koreans is far beyond their own country while studying in South Korea. For the homologous of China and South Koea, traditional culture is more advanced than China. A sense of anxiety emerged--has ancestor culture in China disappeared gradually?nThe Book of Songs is representative of Chinese traditional culture and Confucianism with quite high value of culture and history. Passing down in China for thousands of years, it reveals flexibility via electronic disp")
_cisplatin-versus-doxorubicin-cyclophosphamide-as-neoadjuvant-treatment-in-germline-brca-carriers-with-her2-negative-bc.webp "Dr Nadine Tung speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about a study evaluating cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative breast cancer.nnShe reports that the primary objective was the pathological complete response rate and contrary to expectations the rate for cisplatin was 18% and withdoxorubicin/cyclophosphamide 26%.nnDr Tung reports that this was not significantly different perhaps meaning")
⏲ 1 min 81 sec ✓ 19-Dec-2019
_real-world-whole-sequencing-data-of-ovarian-cancer-patients-124-john-ambrose-amp-gabriel-funingana-124-gers-2022.webp "Genomics England Research Summit 2022 presents John Ambrosewho talk on how treatment of advanced ovarian cancer patients has improved with the introduction of Poly(ADP-ribose)-polymerase (PARP) inhibitors. Initially, germline or somatic pathogenic variants in BRCA1 or BRCA2 genes were identified as predictive biomarkers for PARP inhibitors. Still, more recently, tumours with homologous recombination deficiency (HRD) are proven to benefit also from PARP inhibition, with HRD having both a progno")
⏲ 10 min 49 sec ✓ 16-May-2022
_prof-massimo-innocenti-hypes-and-hopes-in-cellular-therapies-in-regenerative-othopedic-medicine.webp "Platelet rich plasma is widely used in orthopaedics and it’s well known its benefit in treatment of tendon,ncartilage and muscle pathology, as demonstrated in several clinical studies. Conflicting data from clinicalnstudies appear in literature about use of PRP alone in treatment of bone pathologies. It’s known that suitablencolonization and vascularization of tissue-engineered constructs after transplantation represent critical stepsnfor the success of bone repair. PRP is composed of numero")
Prof. Massimo Innocenti - “Hypes and hopes in cellular therapies in regenerative othopedic medicine”
⏲ 16 min 9 sec ✓ 14-Nov-2014
_alkyl-groups-functional-groups-and-homologous-series.webp "Alkyl Groups, Functional Groups And Homologous Series from homologous")
![[+]](/images/menu.gif){kind=small}